Fig. 3. Knockdown of ASF1B in HeLa cells or xenograft tumors in vivo following AAV-shRNA-ASF1B administration suppressed tumor growth.
Stable ASF1B-shRNA-HeLa cells, as well as their relative controls, were prepared and harvested. A total of 5 × 106 cells were injected subcutaneously into the flank of each nude mouse. Tumor sizes were measured every three days. a Images of tumors after each mouse was euthanized. b Measured tumor volumes. The data show that the ASF1B-shRNA tumors grew more slowly than the scrambled control tumors. c Accumulated tumor weights are shown for mice receiving ASF1B-shRNA HeLa cells and control cells. d The tumors were harvested and then fixed with formalin to prepare slides. IHC was performed to detect the expression of ASF1B. e A total of 5 × 106 HeLa cells were injected subcutaneously into the flank of each nude mouse. AAV-shRNA-ASF1B or AAV-scrambled was injected into the formed tumors, and growth was observed on days 12, 15, 18, and 27. f Images of tumors after each mouse was euthanized. g Measured tumor volumes. The mean volume of tumors after administration was significantly smaller for the AAV‑shRNA-ASF1B group than for the scrambled AAV group. h The tumors were harvested and then fixed with formalin to prepare slides. IHC was performed to detect the expression of ASF1B.